Bispecific Antibodies in DLBCL: Therapeutic Potential

Robert Mancini, PharmD, discusses current DLBCL (diffuse large B cell lymphoma) management approaches, relapse rates, frontline, and subsequent therapies, including emerging treatments like bispecific T-cell engagers and monoclonal antibodies.

Related Keywords

Robert Mancini , ,Emerging Role ,Bispecific Antibodies ,Diffuse Largeb Cell Lymphoma Management ,Diffuse Largeb Cell Lymphoma ,Dlbcl ,Immunotherapy ,Clinical Effectiveness ,Safety Profiles ,Multidisciplinary Care ,Therapy Approaches ,Relapse Rates ,Emerging Treatments ,Bispecifict Cell Engagers ,